Detalhe da pesquisa
1.
Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.
Lancet
; 401(10394): 2124-2137, 2023 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37302395
2.
Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.
Lancet Oncol
; 24(8): 868-880, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37423227
3.
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Lancet
; 395(10237): 1613-1626, 2020 05 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32580883
4.
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.
Lancet Oncol
; 14(11): 1086-1094, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24055415
5.
One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.
Health Technol Assess
; 27(25): 1-176, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37991196
6.
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Lancet Oncol
; 12(2): 127-36, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21236730
7.
First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015).
Radiother Oncol
; 100(1): 93-100, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21752481